The cost of Pembrolizumab (Keytruda) in India can vary significantly depending on factors such as the dosage, the healthcare provider, and whether it is purchased through government or private channels. While specific price lists are not publicly available, pricing typically ranges from approximately ₹60,000 to ₹1,00,000 or more for a single vial of 100 mg [1]. A 200 mg dose would therefore be expected to cost approximately double this amount.
How is Pembrolizumab priced in India?
Pembrolizumab's pricing in India is influenced by several market dynamics. The drug is administered intravenously and is used to treat various cancers, including melanoma, lung cancer, and kidney cancer, often as a first-line therapy [2]. The overall cost for a course of treatment can be substantial, running into lakhs of rupees. Generic versions of Pembrolizumab are not yet available due to patent protections [3].
When does the patent for Pembrolizumab expire?
The patent landscape for Pembrolizumab is complex, with various patents covering different aspects of the drug, including its composition of matter and methods of use. DrugPatentWatch.com tracks these patents and their expiry dates. Generally, the main composition of matter patents for Pembrolizumab are expected to expire around 2028 in major markets, though this can vary by country and specific patent [3]. This expiry is crucial for the potential introduction of biosimilar versions.
Can biosimilars enter the Indian market before patent expiry?
The entry of biosimilars for Pembrolizumab in India before the expiry of all relevant patents is unlikely. Biosimilar development requires rigorous clinical trials to demonstrate similarity to the reference product, and regulatory approval hinges on patent status. Manufacturers typically await patent expiry or navigate licensing agreements to launch biosimilar products legally [3].
What are the potential alternatives to Pembrolizumab in India?
For patients in India, treatment options for cancers where Pembrolizumab is used can include other immunotherapy drugs, chemotherapy, radiation therapy, or targeted therapies, depending on the specific cancer type, stage, and individual patient factors [2]. The availability and cost of these alternatives also vary.
How does Pembrolizumab treatment impact patient costs?
Pembrolizumab is an expensive medication, and its cost is a significant consideration for patients and healthcare systems. Many patients may rely on compassionate use programs, insurance coverage, or hospital-based financial assistance schemes to afford treatment. The duration of treatment can also extend over several months or years, further increasing the total expenditure [2].
What is the regulatory status of Pembrolizumab in India?
Pembrolizumab has received approval from the Indian regulatory authorities for several indications [2]. The drug is available in India through the manufacturer, Merck & Co. (known as MSD outside the US and Canada) [1].
Sources:
[1] DrugPatentWatch.com
[2] National Health Mission, India
[3] U.S. Food & Drug Administration